The Ministry of Health announces that the medicinal product Paxlovid (PF-07321332 150 mg/ ritonavir 100 mg) coated tablets is available for prescribing to patients in and outside the GHS with laboratory-confirmed (PCR or Rapid Ag Test) mild or moderate COVID-19 disease, who do not require hospitalisation for severe or critical COVID-19 disease, within 5 days of the date of onset of symptoms or date of test (whichever occurs first) and with at least one risk factor.
For patients within the GHS, before prescribing, treating physicians are asked to respond to a questionnaire that is posted on the GHS IT system to ensure that only those patients who meet the criteria set by the Ministry of Health's ad-hoc committee to create and implement the relevant protocols related to COVID-19 medication are prescribed.
For patients outside the GHS or for prescribing by physicians who are not contracted with the GHS, the questionnaire is posted on the Ministry of Health's COVID-19 website and is available at the following link https:/www.pio.gov.cy/coronavirus/categories/emvoliasmoi-kata-tou-koronoiou (announcement date 11-05-2022)
Paxlovid is prescribed by the following physicians:
- Adult Personal Physicians
- Internists
- Physicians Specializing in Infectious Diseases
- Pulmonologists
- Hematologists
- Internists- Oncologists
- Cardiologists
- Nephrologists
- Nephrologists
- Neurologists
- Rheumatologists
- Endocrinologists
- Geriatricians
- Gastroenterologists
- Oncologists-Radiotherapists
The pharmaceutical product Paxlovid is available only from the following hospital pharmacies of OKYPY: Nicosia, Limassol, Limassol, Larnaca, Famagusta, Pafos General Hospitals and Troodos and Polos Chrysochous Hospitals.
Please note that there is NO supplement (1€) for the medicinal product Paxlovid.
Important information about Paxlovid
The medicinal product Paxlovid is authorised by the European Medicines Agency (EMA).
You are required to consult the Summary of Product Characteristics (SmPC) regarding contraindications, special warnings/precautions and interactions of Paxlovid with other medicinal products.
The SmPC and all relevant product information is available at the following link: https:/www.ema.europa.eu/en/medicines/human/EPAR/paxlovid#product-information-section
Reporting of suspected adverse reactions with the drug Paxlovid
Healthcare professionals are asked to report any suspected adverse reactions through the national reporting system to the Department of Health Pharmaceutical Services by electronic submission to the link Yellow Card or to the following contact details:
Pharmaceutical Services
Ministry of Health
CY-1475 Nicosia
Tel: +357 22608607
Fax: + 357 22608669
Website: www.moh.gov.cy/phs
(AΦ)
Contents of this article including associated images are belongs PIO
Views & opinions expressed are those of the author and/or PIO
Source
